Sebaceous gland disorder

disease
On this page

Also known as disease of sebaceous glanddisease or disorder of sebaceous glanddisorder of sebaceous glandsebaceous gland diseasesebaceous gland disease or disorder

Summary

Sebaceous gland disorder (MONDO:0006607) is a disease (an umbrella term covering 7 Mondo subtypes) with 45 GWAS associations across 13 studies and 3 clinical trials. A subtype of disorder of pilosebaceous unit — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

  • Umbrella term: 7 Mondo subtypes
  • GWAS associations: 45
  • Clinical trials: 3

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

FieldValue
Canonical namesebaceous gland disorder
Mondo IDMONDO:0006607
EFOEFO:1000763
MeSHD012625
DOIDDOID:9098
SNOMED CT3441005
UMLSC0036502
MedGen48599
Anatomy (UBERON)UBERON:0001821
Is cancer (heuristic)no

Also known as: disease of sebaceous gland · disease or disorder of sebaceous gland · disorder of sebaceous gland · sebaceous gland disease · sebaceous gland disease or disorder

Data availability: 45 GWAS associations (13 studies).

Disease family

This is a subtype of disorder of pilosebaceous unit. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › integumentary system disorder › disorder of pilosebaceous unitsebaceous gland disorder

Related subtypes (8): piedra, hypotrichosis, hair follicle neoplasm, folliculitis, hair anomaly, hypertrichosis, Katsantoni-Papadakou-Lagoyanni syndrome, trichostasis spinulosa

Subtypes (7): internal hordeolum, alopecia mucinosa, sebaceous gland neoplasm, sebocystomatosis, acne, demodicidosis of sebaceous gland, rhinophyma

Genetics & variants

GWAS landscape

45 GWAS associations across 13 studies. Top hits map to 18 distinct genes (as reported by GWAS).

Top associations by p-value

rsIDp-valueGeneRisk alleleOdds ratio
rs618167612e-126FLG, CCDSTG0.74
rs754958431e-59PLCD1G0.27
rs122035923e-47IRF4C0.13
rs4523848e-41CLPTM1LT0.08
rs42687481e-39DEF8T0.09
rs4212842e-39CLPTM1LT0.07
chr16:898933753e-39C0.15
rs18050075e-35MC1RC0.21
rs168919821e-19SLC45A2C0.15
rs60596552e-19RALYA0.1
rs361150381e-18CDK5R2-AS1, CDK5R2G0.2
rs11268091e-15TYRG0.05
rs49032933e-15TMED10 - RNU4ATAC14PA0.05
chr14:756573511e-13A0.05
chr9:1095414471e-12G0.05
rs783782222e-12TP53T0.2
chr1:1523195724e-12T0.75
rs109786324e-12LINC01505 - RNA5SP292G0.07
chr1:1505137115e-12A0.05
rs95432857e-12RNY1P8 - MARK2P12A0.04
rs115833957e-12U3 - NXNP1A0.04
rs14813627e-12U3 - NXNP1G0.04
rs49709359e-12FALECC0.04
chr3:1221056162e-11G0.05
rs129138322e-11HERC2A0.05
rs80478032e-11ZNF668C0.06
rs169134621e-07LINC02683?
rs1420287546e-07RFX3-DT?

Top studies (by case count)

StudyLead authorYearCasesControlsTitle
GCST90476210Verma A202461,215337,155Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program.
GCST90476215Verma A202420,908399,030Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program.
GCST90478839Verma A202418,62088,589Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program.
GCST90480484Verma A202418,62088,589Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program.
GCST90436631Zhou W20188,948399,255Efficiently controlling for case-control imbalance and sample relatedness in large-scale genetic association studies.
GCST90478837Verma A20246,91746,948Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program.
GCST90476214Verma A20246,523105,977Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program.
GCST90480483Verma A20246,523105,977Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program.
GCST90652173Liu TY20253,830227,516Diversity and longitudinal records: Genetic architecture of disease associations and polygenic risk in the Taiwanese Han population.
GCST90478843Verma A20241,81554,883Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program.

Variant details and genetic-evidence tiers

Tier distribution (top 50 variants)

TierVariants
Tier 1: coding5
Tier 2: splice/UTR1
Tier 3: regulatory0
Tier 4: intronic/intergenic22

MAF distribution

BucketVariants
common (>=0.05)21
low_freq (0.01-0.05)4
rare (<0.01)2
unknown1

Functional consequences

ConsequenceCount
intron_variant11
unknown6
missense_variant4
intergenic_variant4
stop_gained1
synonymous_variant1
3_prime_UTR_variant1

Top variants

rsIDChrPosAllelesMAFConsequenceGenep-valueTier
rs618167611152313385G>A,C,T0.016stop_gainedFLG, CCDST2e-126Tier 1: coding
rs75495843338009720G>A0.031missense_variantPLCD11e-59Tier 1: coding
rs122035926396321C>G,T0.16intron_variantIRF43e-47Tier 4: intronic/intergenic
rs45238451330725T>C0.435intron_variantCLPTM1L8e-41Tier 4: intronic/intergenic
rs42687481689960104T>C0.28intron_variantDEF81e-39Tier 4: intronic/intergenic
rs42128451325475T>C,G0.451intron_variantCLPTM1L2e-39Tier 4: intronic/intergenic
chr16:898933750.2513e-39Tier 4: intronic/intergenic
rs18050071689919709C>A,G,T0.064missense_variantMC1R5e-35Tier 1: coding
rs16891982533951588C>A,G0.037missense_variantSLC45A21e-19Tier 1: coding
rs60596552034077942A>G0.092intron_variantRALY2e-19Tier 4: intronic/intergenic
rs361150382218960489G>A0.027synonymous_variantCDK5R2-AS1, CDK5R21e-18Tier 4: intronic/intergenic
rs11268091189284793G>A0.283missense_variantTYR1e-15Tier 1: coding
rs49032931475189865A>C,G0.498intergenic_variantTMED10 - RNU4ATAC14P3e-15Tier 4: intronic/intergenic
chr14:756573510.4921e-13Tier 4: intronic/intergenic
chr9:1095414470.2591e-12Tier 4: intronic/intergenic
rs78378222177668434T>A,G0.0093_prime_UTR_variantTP532e-12Tier 2: splice/UTR
chr1:1523195720.0064e-12Tier 4: intronic/intergenic
rs109786329106772126G>C0.098intergenic_variantLINC01505 - RNA5SP2924e-12Tier 4: intronic/intergenic
chr1:1505137110.3075e-12Tier 4: intronic/intergenic
rs95432851373238400A>G0.313intergenic_variantRNY1P8 - MARK2P127e-12Tier 4: intronic/intergenic
rs115833951218667821A>G,T0.447intron_variantU3 - NXNP17e-12Tier 4: intronic/intergenic
rs14813621218685403G>A,C0.412intergenic_variantU3 - NXNP17e-12Tier 4: intronic/intergenic
rs49709351150531586C>G,T0.307intron_variantFALEC9e-12Tier 4: intronic/intergenic
chr3:1221056160.1622e-11Tier 4: intronic/intergenic
rs129138321528120472A>C,G0.241intron_variantHERC22e-11Tier 4: intronic/intergenic
rs80478031631068513C>A,T0.427intron_variantZNF6682e-11Tier 4: intronic/intergenic
rs169134621113931038A>G0.05intron_variantLINC026831e-07Tier 4: intronic/intergenic
rs14202875493531898A>Gintron_variantRFX3-DT6e-07Tier 4: intronic/intergenic

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 3.

Phase distribution (across all retrieved trials)

PhaseTrials
Not specified2
PHASE11

Top trials by phase / activity

NCTPhaseStatusTitle
NCT00580736PHASE1COMPLETEDOptical Clearing of the Skin in Conjunction With Laser Treatments
NCT02455895Not specifiedUNKNOWNEfficacy of iLid Cleanser (Avenova) Versus Vehicle on Ocular Skin Flora
NCT05919810Not specifiedCOMPLETEDThe Effects of Oral Probiotics and Herbal Supplementation on the Gut Microbiome and Sebum Excretion Rate in Non-Cystic Acne

No linked Atlas pages yet — the cross-entity mesh grows as the corpus expands.